In general, the risk of calciphylaxis [30], non-atherosclerotic cardiovascular events [27], calcifications [28], and bone fractures [26] seemed to be lower when CKD-MBD therapy included the use of a CaSR modulator. This evidence concerns the gene CASR and chronic kidney disease.